Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Exclusion Criteria

• •1. Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT.
• •2. Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization.
• •3. Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible.
• •4. Known chronic infection with hepatitis B, C, or HIV.
• •5. Is in the pre-engraftment period during RSV infection.
• •6. Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator.
• •7. Any condition requiring mechanical ventilation or vasopressor support at the time of randomization.
• •8. Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated.
• •9. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated.
• •10. Excessive nausea/vomiting at Screening or an inability to swallow capsules.
• •11. Elevation of hepatic enzymes or renal compromise.